title: Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.
authors.forename: Emmanuel
authors.initials: E
authors.lastname: de Maistre
authors.forename: Catherine
authors.initials: C
authors.lastname: Allart
authors.forename: Thomas
authors.initials: T
authors.lastname: Lecompte
authors.forename: Pierre-Edouard
authors.initials: PE
authors.lastname: Bollaert
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects*; D004347:Drug Interactions; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects*; D005473:Fluoxetine / Q000009:adverse effects*; D006470:Hemorrhage / Q000139:chemically induced*; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects*; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D000078222:Tinzaparin; D020246:Venous Thrombosis / Q000188:drug therapy
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D005473:Fluoxetine; D006495:Heparin, Low-Molecular-Weight; D017367:Selective Serotonin Reuptake Inhibitors; D000078222:Tinzaparin